SK Bioscience to conduct phase 3 clinical trial of its COVID-19 vaccine candidate
Updated: 2021-08-30 17:07:16 KST
South Korean drugmaker SK Bioscience says it has begun the third phase of its COVID-19 vaccine candidate clinical trial becoming the country's first homegrown vaccine candidate to enter the final phase.
The company said on Monday that it will conduct trials to around 4-thousand adults, in 14 medical facilities in Korea and some other facilities overseas.
This comes nearly three weeks after the country's drug ministry approved the final stage of trial.
Within the first half of next year, SK Bioscience aims to produce an interim report before seeking final approval.